Coya data supports COYA 301 for Alzheimer’s, says Chardan

Chardan analyst Keay Nakae maintains a Buy rating on Coya Therapeutics with an $11 price target after the company reported additional blood biomarker results from a proof of concept investigator-led open-label study of COYA 301 in mild-to-moderate Alzheimer’s disease. With the caveats that this data comes from a study conducted in a small group of patients, and in an open-label format, the results as provide additional clinical proof of concept for COYA 301’s mechanism of action, the analyst tells investors in a research note.